

JEG-3 | 300222

General information

Description	JEG-3 is a human epithelial cell line derived from a malignant melanoma. It is characterized by its ability to form colonies in soft agar and its resistance to anoikis. JEG-3 cells are highly proliferative and express a variety of markers associated with malignancy, including vimentin and CD44. The cell line is maintained in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS). JEG-3 cells are highly tumorigenic when injected into immunocompromised mice, forming large, well-defined tumors. The cell line is highly sensitive to treatment with the anti-HER2/neu antibody trastuzumab. JEG-3 cells are highly resistant to treatment with the anti-EGFR antibody cetuximab. JEG-3 cells are highly resistant to treatment with the anti-VEGF antibody bevacizumab. JEG-3 cells are highly resistant to treatment with the anti-angiogenic agent thalidomide. JEG-3 cells are highly resistant to treatment with the anti-inflammatory agent dexamethasone. JEG-3 cells are highly resistant to treatment with the anti-cancer drug cisplatin. JEG-3 cells are highly resistant to treatment with the anti-cancer drug paclitaxel. JEG-3 cells are highly resistant to treatment with the anti-cancer drug doxorubicin. JEG-3 cells are highly resistant to treatment with the anti-cancer drug irinotecan. JEG-3 cells are highly resistant to treatment with the anti-cancer drug gemtuzumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug filgrastim. JEG-3 cells are highly resistant to treatment with the anti-cancer drug epoetin alfa. JEG-3 cells are highly resistant to treatment with the anti-cancer drug darbepoetin alfa. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegfilgrastim. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegcarotazumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegcetuximab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegbevacizumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegthasiran. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegnivolumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegatuzumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegcetuximab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegbevacizumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegthasiran. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegnivolumab. JEG-3 cells are highly resistant to treatment with the anti-cancer drug pegatuzumab.
Organism	Human
Tissue	Epithelial
Disease	Melanoma
Metastatic site	None
Applications	Cell culture, drug screening, cancer research
Synonyms	Jeg-3, JEG3, Jeg3, jeg3

Cell culture

Age	1-3 years
Gender	Male
Morphology	Epithelial, rounded
Growth properties	Highly proliferative, anchorage dependent

Characterization and safety

Citation	JEG-3 (ATCC CCL-22) Cytion 300222
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_0363

Product sheet

JEG-3 | 300222

HEK293T, HEK293-1, HEK293T-1

Isoenzymes	PGM3, 1-2, PGM1, 1, ES-D, 1, AK-1, 1, GLO-1, 1-2, G6PD, B
Tumorigenic	Not tumorigenic
Products	HCG, Human Chorionic Gonadotropin (hCG), Human Chorionic Gonadotropin (hCG), Human Chorionic Gonadotropin (hCG)

HEK293T

Culture Medium	EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO ₃ , w: EBSS (EBSS Cytion 820100a)
Supplements	10% FBS + 1% NEAA
Dissociation Reagent	Trypsin
Doubling time	36 h
Subculturing	Cells are seeded in 96-well plates at a density of 10 ⁴ cells per well. After 24 h, the medium is replaced with fresh medium. Cells are harvested after 48 h.
Seeding density	2 x 10 ⁴ cells per well
Fluid renewal	2 x 3 days
Post-Thaw Recovery	Cells are seeded in 96-well plates at a density of 10 ⁴ cells per well. After 24 h, the medium is replaced with fresh medium. Cells are harvested after 48 h.
Freeze medium	Cells are seeded in 96-well plates at a density of 10 ⁴ cells per well. After 24 h, the medium is replaced with fresh medium. Cells are harvested after 48 h.

JEG-3 | 300222

Thawing and
Culturing Cells

1. 将细胞冻存管放入 37°C 水浴中快速解冻，避免反复冻融。解冻后将细胞悬液转移至离心管中，离心（1500g，5min）。弃去上清液，加入适量培养基，轻轻混匀。
2. 将细胞悬液接种至含有培养基的细胞培养瓶中。轻轻晃动培养瓶，使细胞均匀分布。将培养瓶置于 37°C、5% CO₂ 培养箱中培养。
3. 细胞接种后，每天观察细胞生长情况。当细胞达到 70-80% 汇合度时，可进行传代。
4. 传代时，将细胞悬液转移至新的培养瓶中。轻轻晃动培养瓶，使细胞均匀分布。将培养瓶置于 37°C、5% CO₂ 培养箱中培养。
5. 细胞传代时，建议使用 15 mL 离心管或 50 mL 离心瓶。轻轻晃动离心管或离心瓶，使细胞均匀分布。
6. 细胞传代时，建议使用 300 x g 离心力离心 3 分钟。弃去上清液，加入适量培养基，轻轻混匀。
7. 细胞传代时，建议使用 10 mL 离心管或 50 mL 离心瓶。轻轻晃动离心管或离心瓶，使细胞均匀分布。
8. 细胞传代时，建议使用 10-15 mL 离心管或 50-75 mL 离心瓶。轻轻晃动离心管或离心瓶，使细胞均匀分布。

Incubation
Atmosphere

37°C, 5% CO₂, 饱和湿度

Flask Coating

无需涂布

Freezing
Procedure

将细胞悬液转移至冻存管中，加入适量冻存液。轻轻晃动冻存管，使细胞均匀分布。将冻存管置于 -80°C 冰箱中冻存。

Shipping
Conditions

将细胞冻存管放入冰袋中，置于 -80°C 冰箱中保存。运输过程中保持低温，避免反复冻融。

Storage
Conditions

将细胞冻存管放入冰袋中，置于 -80°C 冰箱中保存。运输过程中保持低温，避免反复冻融。

细胞冻存液

Sterility

细胞冻存液经过严格的无菌检测，符合 PCR 级试剂标准。冻存液不含任何抗生素、血清、蛋白酶抑制剂等物质。冻存液在 -80°C 冰箱中可长期保存。

XXXX JEG-3 | 300222

XXXXXX HLA

A*: '01:01:01, '11:01:01
B*: 08:13, 35:01:00
C*: 04:01:01, 07:01:01
DRB1*: '01:03:01, '03:01:01
DQA1*: '01:01:01, '05:01:01
DQB1*: '02:01:01, '05:01:01
DPB1*: '01:01:01, '04:01:01
E: 01:01:01